Comparison of the effects of single predonine and predonine-iguratimod therapy on the old elderly onset arthritis.randomized controlled trial. - The effects of iguratimod therapy on the elderly onset arthritis.

开始日期2016-08-01

申办/合作机构-

100 项与氢化泼尼松琥珀酸钠相关的临床结果

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的转化医学

登录后查看更多信息

100 项与氢化泼尼松琥珀酸钠相关的专利（医药）

登录后查看更多信息

776

项与氢化泼尼松琥珀酸钠相关的文献（医药）

2024-11-01·HemaSphere

Results of the prospective EORTC Children Leukemia Group study 58081 in precursor B‐ and T‐cell acute lymphoblastic leukemia

Article

作者: Uyttebroeck, Anne ; Grardel, Nathalie ; Bakkus, Marleen ; Freycon, Claire ; Kicinski, Michal ; Suciu, Stefan ; Kornreich, Laure ; Domenech, Carine ; Cavé, Hélène ; Rohrlich, Pierre ; Ferster, Alina ; Pluchart, Claire ; Bertrand, Yves ; Philippet, Pierre ; Chahla, Wadih A. ; Poirée, Marilyne ; De Moerloose, Barbara ; Simon, Pauline ; Piette, Caroline ; Theron, Alexandre ; Millot, Frédéric ; Arfeuille, Chloé ; Pasquet, Marlène ; Paillard, Catherine

AbstractHere, we report the results of the prospective cohort study EORTC‐CLG 58081 and compare them to the control arm of the randomized phase 3 trial EORTC‐CLG 58951, on which treatment recommendations were built. In both studies, patients aged 1–18 years with BCR::ABL1 negative acute lymphoblastic leukemia of the B‐lineage (B‐ALL) or T‐lineage (T‐ALL) were treated using a BFM backbone without cranial irradiation. Similarly to the control arm of 58951, prednisolone (PRED) 60 mg/m2/day was used for induction therapy, but a few modifications were made. Dexamethasone (DXM) was used in average‐risk 2 (AR2) T‐ALL and B‐ALL during induction, 10 and 6 mg/m2/day, respectively. Leucovorin rescue was delayed to 42 h instead of 36 h after initiation of high‐dose methotrexate, and a postconsolidation MRD time point was added to stratify patients. Between 2011 and 2017, 835 patients were prospectively enrolled in the 58081 study. Overall, the 5‐year event‐free survival (EFS) was 84.8% versus 83.6% (hazard ratio [HR], 0.96 [95% confidence interval [CI]: 0.76–1.21]) for 58081 versus 58951 considered as a control group, respectively, 84.3% versus 84.9% (HR, 1.06 [99% CI: 0.75–1.49]) in B‐ALL but 87.3% versus 76.6% (HR, 0.59 [99% CI: 0.28–1.24]) in T‐ALL. The comparison between the two studies regarding EFS differed by risk group (p = 0.012). The HR was 2.15 (99% CI: 0.67–6.85) for very low‐risk but 0.34 (99% CI: 0.13–0.89) for AR2. The particularly favorable results observed in the T‐ALLs and AR2 subgroups suggest the benefit of using DXM in specific patient groups and highlight the importance of risk stratification.

2024-04-08·Cureus

Cardiovascular Morbidity in Systemic Lupus Erythematosus: A Single-Center Retrospective Study

Article

作者: Albednah, Fahed A ; Al Harbi, Khalid ; Alammari, Yousef ; Alkahtani, Abdullah H ; Almansour, Mohammed ; Alharbi, Khalid A ; Qutob, Rayan Abubakker ; Alshehry, Hasan Z ; Alsharif, Abdulaziz Y ; Alajaji, Abdulrahman A ; Alrashoudi, Abdulrahman M ; Alsaedi, Ahmed M

BACKGROUNDSystemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition affecting multiple systems. Cardiovascular morbidity is a significant concern, with around 25% of SLE patients experiencing cardiac complications.OBJECTIVEThis study aims to determine the prevalence of cardiovascular morbidity in SLE patients in King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia.METHODOLOGYThis retrospective record-based research was conducted at KFMC from January 2015 to October 2023. A review of the medical files of all SLE patients was accomplished.RESULTSThe vast majority of the patients (90.9%) were females. The mean age for the patients was 36.5 years. The most common comorbidities were lupus nephritis (34.6%), hypothyroidism (18.4%), and anti-phospholipid syndrome (9.2%). The most commonly used medications were hydroxychloroquine (81.8%), corticosteroids (prednisolone) (43.0%), and mycophenolate mofetil (27.9%). Around 45.2% (n= 176) of the patients with SLE developed cardiovascular complications. The most commonly reported cardiovascular diseases that developed after diagnosing patients with SLE were hypertension (22.4%), valvular heart diseases (13.2%), and dyslipidemia (9.2%). The study also found that anti-dsDNA antibodies can reduce the likelihood of developing hypertension by 40%. This research contributes to the medical literature on SLE and sets the stage for future research on personalized healthcare strategies for managing SLE and its complications.CONCLUSIONThis study highlights that a considerable proportion of SLE patients(~50%) develop cardiovascular complications, with hypertension, valvular heart diseases, and dyslipidemia being the most common. We also discovered that anti-double-stranded deoxyribonucleic acid antibodies (Anti-dsDNA) reduce the likelihood of developing hypertension.

2024-04-01·Acta Biomaterialia

pH-responsive size-adjustable liposomes induce apoptosis of fibroblasts and macrophages for rheumatoid arthritis treatment

Article

作者: Liu, Yan ; Tang, Jun ; Mao, Jingying ; Nie, Yu ; Yang, Hong ; Liang, Xiaoya ; Zhou, Xiangyu ; Zhang, Zongquan ; Yang, Xi ; Li, Chunhong ; Wang, Chenglong ; Zheng, Xiu

In rheumatoid arthritis (RA), macrophages infiltrate joints, while fibroblast-like synovial cells proliferate abnormally, forming a barrier against drug delivery, which hinders effective drug delivery to joint focus. Here we firstly designed a pH-responsive size-adjustable nanoparticle, composed by methotrexate (MTX)-human serum albumin (HSA) complex coating with pH-responsive liposome (Lipo/MTX-HSA) for delivering drugs specifically to inflamed joints in acidic environments. We showed in vitro that the nanoparticles can induce mitochondrial dysfunction, promote apoptosis of fibroblast-like synoviocytes and macrophages, further reduce the secretion of inflammatory factors (TNF-α, IL-1β, MMP-9), and regulate the inflammatory microenvironment. We also demonstrated similar effects in a rat model of arthritis, in which Lipo/MTX-HSA accumulated in arthritic joints, and at low pH, liposome phospholipid bilayer cleavage released small-sized MTX-HSA, which effectively reduced the number of fibroblast-synoviocytes and macrophages in joints, alleviated joint inflammation, and repaired bone erosion. These findings suggest that microenvironment-responsive size-adjustable nanoparticles show promise as a treatment against rheumatoid arthritis. STATEMENT OF SIGNIFICANCE: Abnormal proliferation of fibroblast synoviocytes poses a physical barrier to effective nanoparticle delivery. We designed size-adjustable nano-delivery systems by preparing liposomes with cholesterol hemisuccinate (CHEM), which were subsequently loaded with small-sized albumin nanoparticles encapsulating the cytotoxic drug MTX (MTX-HSA), termed Lipo/MTX-HSA. Upon tail vein injection, Lipo/MTX-HSA could be aggregated at the site of inflammation via the ELVIS effect in the inflamed joint microenvironment. Specifically, intracellular acidic pH-triggered dissociation of liposomes promoted the release of MTX-HSA, which was further targeted to fibroblasts or across fibroblasts to macrophages to exert anti-inflammatory effects. The results showed that liposomes with adjustable particle size achieved efficient drug delivery, penetration and retention in joint sites; the strategy exerted significant anti-inflammatory effects in the treatment of rheumatoid arthritis by inducing mitochondrial dysfunction to promote apoptosis in fibrosynoviocytes and macrophages.

100 项与氢化泼尼松琥珀酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01239	氢化泼尼松琥珀酸钠	D07XA02 D07AA03 S02BA03 A07EA01 C05AA04 S03BA02 S01CB02 H02AB06 R01AD02 S01BA04	DB14633

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
粘膜皮肤淋巴结综合征	日本	Shionogi Pharma Co., Ltd.	2013-09-13
肾上腺皮质疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
强直性脊柱炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
哮喘	日本	Shionogi Pharma Co., Ltd.	1960-12-24
胶原蛋白疾病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
脑脊髓炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肉芽肿伴多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
心脏衰竭	日本	Shionogi Pharma Co., Ltd.	1960-12-24
幼年特发性关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
白血病	日本	Shionogi Pharma Co., Ltd.	1960-12-24
显微镜下多血管炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性硬化症	日本	Shionogi Pharma Co., Ltd.	1960-12-24
重症肌无力	日本	Shionogi Pharma Co., Ltd.	1960-12-24
多发性肌炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
肺纤维化	日本	Shionogi Pharma Co., Ltd.	1960-12-24
风湿热	日本	Shionogi Pharma Co., Ltd.	1960-12-24
类风湿关节炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24
系统性红斑狼疮	日本	Shionogi Pharma Co., Ltd.	1960-12-24
亚急性甲状腺炎	日本	Shionogi Pharma Co., Ltd.	1960-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MP87-07 (AUA2015)	临床2期	去势抵抗性前列腺癌	120	Intermittent Docetaxel and Prednisolone (DP)	構艱鑰艱觸壓網顧範積(鬱憲遞製衊糧襯憲鹹襯) = 築觸鹹醖顧壓築艱膚蓋鏇遞鏇積夢鹽膚壓築蓋 (鹽窪廠齋襯製觸鏇壓願 ) 更多	-	2015-04-01
MRC Myeloma IX (Pubmed \| Circulation)	N/A	多发性骨髓瘤	-	Cyclophosphamide, thalidomide, and dexamethasone (CTDa)	(醖鹹獵鹹鏇築襯齋獵糧) = CTDa was associated with higher rates of constipation 獵襯壓淵齋鹽積遞願憲 (鹽遞襯獵簾選觸膚醖夢 ) 更多	-	2011-08-04
MRC Myeloma IX (Pubmed \| Circulation)	N/A	多发性骨髓瘤	-	Melphalan and prednisolone (MP)		-	2011-08-04